SCYNEXIS, Inc.

NASDAQ:SCYX

0.9 (USD) • At close April 17, 2025
Bedrijfsnaam SCYNEXIS, Inc.
Symbool SCYX
Munteenheid USD
Prijs 0.904
Beurswaarde 35,250,609
Dividendpercentage 0%
52-weken bereik 0.728 - 3.07
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. David Gonzalez Angulo M.D.
Website https://www.scynexis.com

An error occurred while fetching data.

Over SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal

Vergelijkbare Aandelen

Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

BOLT

0.35 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.253 USD

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

0.561 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

2.62 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.003 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)